Mexican Chiapas Coffee (Coffea arabica 'Mexican Chiapas')
Mexican Chiapas Coffee (Coffea arabica 'Mexican Chiapas') is a specialty arabica cultivar grown in the highland regions of Chiapas, Mexico, containing caffeine (1.1–1.7%) and chlorogenic acids that act as adenosine receptor antagonists and antioxidants respectively. No clinical trials have isolated this specific cultivar, so its health profile is extrapolated from general Coffea arabica research.

Origin & History
Mexican Chiapas Coffee refers to Coffea arabica cultivars grown in the high-altitude Chiapas region of Mexico, where volcanic soils and equatorial proximity create beans with distinctive chocolate-almond flavors, high acidity, and floral-fruity aromas. The coffee contains 1.1-1.7% caffeine and received Denomination of Origin status in 2003 for its unique sensory profile.
Historical & Cultural Context
Mexican Chiapas Coffee has no documented historical use in traditional medicine systems according to the research. It is primarily valued for its culinary and organoleptic qualities influenced by altitude and soil conditions, receiving Denomination of Origin status in 2003 for its sensory profile rather than medicinal applications.
Health Benefits
• No clinical health benefits documented - no human trials specific to Mexican Chiapas Coffee were identified in the research • General coffee compounds include chlorogenic acids (up to 14% in green seeds) - evidence quality: not studied for this cultivar • Contains caffeine (1.1-1.7%) as a natural stimulant - evidence quality: no specific clinical data for Chiapas variant • Rich in tannins (3-5%) and other polyphenols - evidence quality: chemical composition only, no health outcome studies • Contains proteins (13%) and fixed oils (10-15%) - evidence quality: compositional data only, no clinical significance established
How It Works
Caffeine (1.1–1.7% dry weight) competitively antagonizes adenosine A1 and A2A receptors in the central nervous system, reducing adenosine-mediated inhibition and increasing dopaminergic and noradrenergic neurotransmission. Chlorogenic acids (up to 14% in green beans), particularly 5-caffeoylquinic acid, inhibit glucose-6-phosphatase and slow intestinal glucose absorption, modulating postprandial glycemia. These same chlorogenic acids scavenge reactive oxygen species and may upregulate Nrf2-mediated antioxidant enzyme expression, though these pathways have not been confirmed in studies specific to the Chiapas cultivar.
Scientific Research
No human clinical trials, RCTs, or meta-analyses specific to Mexican Chiapas Coffee (Coffea arabica 'Mexican Chiapas') were identified in the research. While general coffee studies exist, including references to organic vs. conventional Coffea arabica composition, none specifically target this cultivar or provide PMIDs for Chiapas-specific health outcomes.
Clinical Summary
No human clinical trials have been conducted specifically on Mexican Chiapas Coffee as a distinct cultivar, making direct evidence impossible to cite. General Coffea arabica research includes large epidemiological cohorts — such as the EPIC study (>500,000 participants) — associating 3–4 daily cups with reduced risk of type 2 diabetes and liver disease, but cultivar-specific contributions cannot be isolated. Green coffee extract trials (e.g., Vinson et al., 2012, n=16) using 700–1,050 mg of standardized chlorogenic acid showed modest weight and blood pressure effects, but these used commercial extracts, not Chiapas-origin beans. Overall, evidence quality for this specific cultivar is absent, and any benefits attributed to it are inferred from broader arabica and green coffee research.
Nutritional Profile
Mexican Chiapas Coffee (green/roasted bean basis, per 100g dry weight): Protein 10-13g (green bean), reduced to 8-10g post-roast due to Maillard reactions; Carbohydrates 38-42g (green bean) including sucrose 6-9g (largely degraded during roasting to ~1-2g); Dietary fiber 33-40g (green bean, primarily insoluble polysaccharides: mannans, cellulose, pectin); Fat 12-18g (green bean, predominantly linoleic acid ~45% of lipid fraction, palmitic acid ~30%, oleic acid ~10%); Moisture 10-12% (green bean), 1-5% (roasted). Bioactive compounds: Caffeine 1.1-1.7% (11-17mg/g green bean); Chlorogenic acids (CGAs) up to 14% in green seeds (primary isomers: 5-caffeoylquinic acid ~6-8%, 3-caffeoylquinic and 4-caffeoylquinic acids ~1-2% each), substantially degraded to 3-7% in light roast and 1-2% in dark roast; Tannins 3-5% (condensed and hydrolyzable forms, including trigonelline precursor complexes); Trigonelline 0.6-1.2% (green bean), degrades to niacin (vitamin B3) during roasting yielding approximately 10-40mg niacin per 100g roasted bean; Diterpenes (cafestol and kahweol) 0.2-0.8% of lipid fraction, present in unfiltered preparations, largely removed by paper filtration; Melanoidins 25-30% of roasted bean dry weight (formed via Maillard reactions, exhibit antioxidant and prebiotic properties). Minerals (per 100g roasted bean): Potassium 1,600-2,000mg (high bioavailability in brewed form ~70-80% extraction); Magnesium 160-200mg; Phosphorus 140-180mg; Manganese 1.0-2.0mg; Iron 2-4mg (low bioavailability, ~5-10%, inhibited by CGAs); Copper 0.2-0.4mg; Calcium 120-160mg. Vitamins: Niacin (B3) 10-40mg per 100g roasted (derived from trigonelline pyrolysis); Riboflavin (B2) trace ~0.1-0.2mg; Pantothenic acid ~1.0mg. Bioavailability notes: In brewed coffee (standard 10g/100ml), approximately 60-80% of caffeine, 30-50% of CGAs, and 80-90% of potassium are extracted; high-altitude Chiapas growing conditions (900-1,500m) associated with slower cherry maturation and potentially elevated CGA and sucrose concentrations relative to lowland arabica, though cultivar-specific extraction data are not formally documented in peer-reviewed literature.
Preparation & Dosage
No clinically studied dosage ranges for Mexican Chiapas Coffee in any form (extract, powder, or standardized) were found, as no human trials exist for this specific cultivar. General caffeine content is 1.1-1.7% in Chiapas Coffea arabica beans. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Green tea extract, L-theanine, rhodiola, guarana, yerba mate
Safety & Interactions
Caffeine content of 1.1–1.7% means a standard 8 oz brewed cup delivers approximately 80–120 mg caffeine, which can cause insomnia, tachycardia, anxiety, and hypertension at higher intakes exceeding 400 mg/day in healthy adults. Caffeine interacts with adenosine-based medications, monoamine oxidase inhibitors (MAOIs), and fluoroquinolone antibiotics, which inhibit CYP1A2-mediated caffeine metabolism and can substantially raise plasma caffeine levels. Pregnant individuals are advised to limit total caffeine intake to under 200 mg/day (WHO/ACOG guidance) due to associations with low birth weight and preterm delivery. Individuals with cardiac arrhythmias, severe hypertension, anxiety disorders, or GERD should use caffeinated coffee with caution or under medical supervision.